Jazz Pharmaceuticals acquires North, South American rights to defibrotide
- Jazz has acquired rights to defibrotide in the Americas. The company already has rights in Europe where the drug has been marketed as Defitelio since EMA approval in October 2013.
- Defibrotide is for treatment of severe hepatic veno-occlusive disease in patients over month of age who are undergoing hematopoietic stem cell transplantation therapy.
- Total payments from Jazz to Sigma-Tau, including an upfront payment and milestone payments, are $250 million.
Jazz has acquired rights to the defibrotide NDA and is now engaged in the hard work of gaining FDA approval for treatment of VOD infections in HSCT patients.
Payments include $75 million up front, $25 million for acceptance from FDA to file the NDA and an additional $150 million upon FDA approval -- depending on timing. Jazz will fund all payouts from cash on hand.